Obesity in women is a multifaceted, chronic, relapsing remitting metabolic condition, influenced by interactions across the reproductive and life-course. 1 Emerging data reinforce the impact of life-course obesity on women’s long-term health. Early-life factors such as childhood SES, maternal weight, and reproductive milestones (menarche, PCOS, gestational weight changes, menopause) can program metabolic trajectories and later-life obesity, diabetes, and even endometrial cancer risk. 2 GLP 1 receptor agonists like semaglutide represent a paradigm shift.

In the STEP 1 trial, semaglutide 2.4 mg weekly delivered a mean weight loss of –14.9% over 68 weeks versus –2.4% with placebo—nearly 70% of participants lost ≥10% body weight. 3 Notably, postmenopausal women on hormone therapy exhibited better responses to semaglutide than those without HRT (16% vs 12% total weight loss at one year). 4…